Asthma - Completed
- Cipla U-FS-MU-AS3120: A Multicenter, Randomized, Parallel-Group, Placebo-Controlled, 4-week Clinical Endpoint Bioequivalence Study Comparing Fluticasone Propionate/Salmeterol 100/50 µg inhalation powder (Cipla Ltd., India) with Advair®Diskus 100/50 µg (GlaxoSmithKline, USA) in Asthma Patients
- Gossamer GB001-2001: A Phase 2b, randomized, double-blind, placebo-controlled, dose-ranging, multi-center study to evaluate the efficacy and safety of GB001 as maintenance therapy in adult subjects with moderate to severe asthma
- Amphastar API-A008-BE-PD: A Randomized, Single-Dose, Double-Blind, Double-Dummy, Placebo-Controlled, Five-Treatment, Crossover PD Study
- TEVA TPI-18-03: A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg in Adult Subjects with Asthma
- AstraZeneca D3250C00045: A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Phase 3b Study to Evaluate the Safety and Efficacy of Benralizumab 30 mg SC in Patients with Severe Asthma Uncontrolled on Standard of Care Treatment
- Kindeva CSP-07-000034: Randomized, Single Blind, Parallel Group, Placebo Controlled, Multidose Study Comparing the Therapeutic Equivalence of a 3M Budesonide/Formoterol Fumarate Inhaler and a Symbicort® Reference Inhaler in Adult Subjects With Asthma
- Hoffmann-La Roche GB28689: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication
- Teva BDB-AS-302: A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, 12-Week Clinical Study to Assess the Efficacy and Safety of 80 or 160 mcg/Day of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Pediatric Patients 4 Through 11 Years of Age With Persistent Asthma
- AstraZeneca D589GC00003: A Phase 3, 12-Week, Double-Blind, Randomized, Parallel-Group, Multicenter Study Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg, 2 Actuations Twice Daily, and Symbicort pMDI 80/4.5 μg, 2 Actuations Twice Daily, Compared With Budesonide pMDI 80 μg, 2 Actuations Twice Daily, in Children Ages 6 to <12 Years With Asthma
- Teva FSS-AS-30003: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients Aged 4 Through 11 Years With Persistent Asthma
- Merck 0887A-087: A Phase III, Randomized, Active-Controlled, Parallel-Group Clinical Trial to Study the Efficacy and Long-Term Safety of Mometasone Furoate/Formoterol Fumarate (MF/F, MK-0887A [SCH418131]), Compared With Mometasone Furoate (MF, MK-0887 [SCH032088]), in Children With Persistent Asthma
- Sanofi EFC13579: A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma
- GSK 201832: A Randomised, Double-Blind, Double-Dummy, Crossover Comparison of Fluticasone Furoate/Vilanterol 100/25 mcg Once Daily Versus Fluticasone Propionate 250 mcg Twice Daily in Adolescent and Adult Subjects With Asthma and Exercise-Induced Bronchoconstriction
- Teva FSS-AS-30017: A 12-Week, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone/Salmeterol Multidose Dry Powder Inhaler in Adolescent and Adult Patients With Persistent Asthma Symptomatic Despite Inhaled Corticosteroid Therapy
- Teva FSS-AS-305: A 26-Week Open-Label Study to Assess the Long-Term Safety of Fluticasone Propionate Multidose Dry Powder Inhaler and Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients 12 Years of Age and Older With Persistent Asthma
- Teva BDB-AS-30039: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 6-Week Clinical Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) at 320 or 640 mcg/Day in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma
- Teva FSS-AS-301: A 12-Week, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone/Salmeterol Multidose Dry Powder Inhaler in Adolescent and Adult Patients With Persistent Asthma Symptomatic Despite Low-dose or or Mid-dose Inhaled Corticosteroid Therapy
- AstraZeneca D5180C00007: A Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents With Severe Uncontrolled Asthma (NAVIGATOR)
- West-Ward Columbus FLSA-P100/50-PVCL-2: A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 μg and Salmeterol Xinafoate 50 μg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
- Novartis CQAW039A2316: A 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma
- Teva ACT-2015-075-0AA: A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter, Multinational Study to Compare the Therapeutic Equivalence of a Budesonide 80 μg/Formoterol Fumarate Dihydrate 4.5 μg Inhalation Aerosol (Manufactured by Catalent for Watson Laboratories Inc.) to Symbicort® (Budesonide 80 μg/Formoterol Fumarate Dihydrate 4.5 μg Inhalation Aerosol) (Manufactured by AstraZeneca) in Adolescent and Adult Patients With Asthma
- Novartis CQAW039A2316: A 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma
- Novartis CCSJ117A12201C: A 12-Week, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Study to Assess the Efficacy and Safety of CSJ117, when Added to Existing Asthma Therapy in Patients ≥18 Years of Age with Severe Uncontrolled Asthma.
- Suzhou Connect CBP-201-WW002: A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Efficacy and Safety Study of CBP-201 in Adult Patients with Moderate to Severe Persistent Asthma with Type 2 Inflammation.
Food Allergy - Completed
- Aimmune ARC007: Real World AR101 Market Supporting Experience Study in Peanut Allergic Children Ages 4 to 17 years (RAMSES)
- Regeneron R668-ALG-16114: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study In Pediatric Subjects With Peanut Allergy To Evaluate The Efficacy And Safety Of Dupilumab As Adjunct To AR101 (Peanut Oral Immunotherapy).
- Nestle 16.16.CLI: Evaluation of Hypoallergenicity of a New Extensively Hydrolyzed Formula
- DBV REALISE V712-EAP01: Long-Term Assessment of Safety and Therapeutic Benefit of Viaskin Peanut Epicutaneous Treatment in Peanut-Allergic Children: A 6-month Randomized, Double-Blind, Placebo-Controlled Phase III Study Followed by An Open Label Active Treatment (REALISE Study)
- Aimmune ARC003: Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)
- Novartis CQGE031G12301: A 52 week, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study to Assess the Clinical Efficacy and Safety of Ligelizumab (QGE031) in Decreasing the Sensitivity to Peanuts in Children and Adult Patients with Peanut Allergy.
- Alladapt ADP101-MA-01: A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults (The Harmony Study).
- COUR CNP-201-5.002: A Phase 1b/2a Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of CNP-201 in Subjects Ages 16-55 with Peanut Allergy.
Nasal Polyps - Completed
- Hoffmann-La Roche GA39688: A Phase III, randomized, multicenter, double-blind, placebo-controlled clinical trial of omalizumab in patients with Chronic Rhinosinusitis with Nasal Polyps
Atopic Dermatitis - Completed
- AbbVie M16-045: A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis
- Incyte INCB 18424-304: A Phase 3, Double-Blind, Randomized, 8-week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults with Atopic Dermatitis
- Pfizer B7451029: A Phase 3 Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Multi-Center Study Investigating The Efficacy and Safety of PF-04965842 and Dupilumab in Comparison with Placebo in Adult Subjects on Background Topical Therapy, With Moderate to Severe Atopic Dermatitis.
- Regeneron R668-AD-1652: A Randomized, Double-Blind, Placebo-Controlled Study To Investigate the Efficacy and Safety of Dupilumab Administered Concomitantly with Topical Corticosteroids in Patients ≥ 6 Years To <12 Years of Age with Severe Atopic Dermatitis
- Pfizer B7451036: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Investigating The Efficacy and Safety of PF-04965842 Co-Administered With Background Medicated Topical Therapy in Adolescent Participants 12 to < 18 years of age with Moderate to Severe Atopic Dermatitis.
- Hoffmann-La Roche GS29735: An Open-Label Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Persistent, Moderate to Severe Atopic Dermatitis
- Regeneron R668-AD-1314: A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
- Dermavant DMVT-505-3101: A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Moderate to Severe Atopic Dermatitis in Children and Adults
- Dermavant DMVT-505-3103: An Open-Label, Long-Term Extension Study to Evaluate the Safety and Efficacy of Tapinarof Cream 1% in Subjects with Atopic Dermatitis
- Incyte INCB 18424-304: A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis (TRuE-AD2).
- Incyte INCB 18424-305: A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages ≥ 2 Years to < 12 Years) With Atopic Dermatitis (TRuE-AD3).
Chronic Cough - Completed
- Vyne MTI-110: A randomized, double-blind, placebo-controlled study of the efficacy, safety and tolerability of serlopitant for the treatment of refractory chronic cough
- Attenua ATA101-PN-001: A Dose Escalation Study to Assess the Efficacy and Safety of ATA-101 in Subjects with Refractory Chronic Cough
- Bellus BUS-P2-02: A Randomized, Adaptive, Double-Blind, Placebo-Controlled, Parallet-Arm Phase 2b Study to Evaluate the Efficacy and Safety of Multiple Doses of BLU-5937 in Adult Participants With Refractory Chronic Cough
